Alto Neuroscience, Inc. ANRO
We take great care to ensure that the data presented and summarized in this overview for Alto Neuroscience, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ANRO
Top Purchases
Top Sells
About ANRO
Insider Transactions at ANRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
2,931
+6.85%
|
$38,103
$13.22 P/Share
|
|
Jul 09
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
12,069
+13.37%
|
$144,828
$12.84 P/Share
|
|
Mar 28
2024
|
Nicholas Conrad Smith CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
6,150
+10.59%
|
$98,400
$16.18 P/Share
|
|
Mar 01
2024
|
Amit Etkin PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
34,711
+2.72%
|
-
|
|
Mar 01
2024
|
Nicholas Conrad Smith CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
19,153
+48.04%
|
-
|
|
Feb 06
2024
|
Apeiron Investment Group Ltd. |
BUY
Conversion of derivative security
|
Indirect |
674,658
+50.0%
|
-
|
|
Feb 06
2024
|
Apeiron Investment Group Ltd. |
BUY
Conversion of derivative security
|
Direct |
251,881
+50.0%
|
-
|
|
Feb 06
2024
|
Alpha Wave Global, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600,000
+13.93%
|
$9,600,000
$16.0 P/Share
|
|
Feb 06
2024
|
Alpha Wave Global, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,107,757
+38.46%
|
-
|
|
Feb 06
2024
|
Nicholas Conrad Smith CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
1,563
+50.0%
|
$25,008
$16.0 P/Share
|
|
Feb 06
2024
|
Gwill York Director |
BUY
Conversion of derivative security
|
Direct |
23,917
+50.0%
|
-
|
|
Feb 06
2024
|
Po Yu (Jeff) Chen |
BUY
Conversion of derivative security
|
Direct |
47,709
+32.52%
|
-
|
|
Feb 06
2024
|
Amit Etkin PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
3,125
+0.26%
|
$50,000
$16.0 P/Share
|
|
Feb 06
2024
|
Amit Etkin PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
11,777
+0.97%
|
-
|
|
Feb 06
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
17,000
+40.62%
|
$272,000
$16.0 P/Share
|
|
Feb 06
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Conversion of derivative security
|
Indirect |
7,851
+50.0%
|
-
|
|
Feb 06
2024
|
Christopher Nixon Cox Director |
BUY
Conversion of derivative security
|
Indirect |
715,653
+32.52%
|
-
|
Last 12 Months Summary
Buy / Acquisition
75K
Shares
From
4
Insiders
| Open market or private purchase | 21.2K shares |
|---|---|
| Grant, award, or other acquisition | 53.9K shares |
Sell / Disposition
0
Shares
From
0
Insiders